252 related articles for article (PubMed ID: 28508873)
1. Mutant KRAS promotes malignant pleural effusion formation.
Agalioti T; Giannou AD; Krontira AC; Kanellakis NI; Kati D; Vreka M; Pepe M; Spella M; Lilis I; Zazara DE; Nikolouli E; Spiropoulou N; Papadakis A; Papadia K; Voulgaridis A; Harokopos V; Stamou P; Meiners S; Eickelberg O; Snyder LA; Antimisiaris SG; Kardamakis D; Psallidas I; Marazioti A; Stathopoulos GT
Nat Commun; 2017 May; 8():15205. PubMed ID: 28508873
[TBL] [Abstract][Full Text] [Related]
2. Mast cells mediate malignant pleural effusion formation.
Giannou AD; Marazioti A; Spella M; Kanellakis NI; Apostolopoulou H; Psallidas I; Prijovich ZM; Vreka M; Zazara DE; Lilis I; Papaleonidopoulos V; Kairi CA; Patmanidi AL; Giopanou I; Spiropoulou N; Harokopos V; Aidinis V; Spyratos D; Teliousi S; Papadaki H; Taraviras S; Snyder LA; Eickelberg O; Kardamakis D; Iwakura Y; Feyerabend TB; Rodewald HR; Kalomenidis I; Blackwell TS; Agalioti T; Stathopoulos GT
J Clin Invest; 2015 Jun; 125(6):2317-34. PubMed ID: 25915587
[TBL] [Abstract][Full Text] [Related]
3. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
4. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.
Roscilli G; De Vitis C; Ferrara FF; Noto A; Cherubini E; Ricci A; Mariotta S; Giarnieri E; Giovagnoli MR; Torrisi MR; Bergantino F; Costantini S; Fenizia F; Lambiase M; Aurisicchio L; Normanno N; Ciliberto G; Mancini R
J Transl Med; 2016 Feb; 14():61. PubMed ID: 26928703
[TBL] [Abstract][Full Text] [Related]
5. Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion.
Marazioti A; Kairi CA; Spella M; Giannou AD; Magkouta S; Giopanou I; Papaleonidopoulos V; Kalomenidis I; Snyder LA; Kardamakis D; Stathopoulos GT
PLoS One; 2013; 8(8):e71207. PubMed ID: 23967166
[TBL] [Abstract][Full Text] [Related]
6. Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion.
Psallidas I; Stathopoulos GT; Maniatis NA; Magkouta S; Moschos C; Karabela SP; Kollintza A; Simoes DC; Kardara M; Vassiliou S; Papiris SA; Roussos C; Kalomenidis I
Oncogene; 2013 Jan; 32(4):528-35. PubMed ID: 22370646
[TBL] [Abstract][Full Text] [Related]
7. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
Tsai TH; Su KY; Wu SG; Chang YL; Luo SC; Jan IS; Yu CJ; Yu SL; Shih JY; Yang PC
Eur Respir J; 2012 Mar; 39(3):677-84. PubMed ID: 21719485
[TBL] [Abstract][Full Text] [Related]
8. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion.
Liu Y; Wang L; Song Q; Ali M; Crowe WN; Kucera GL; Hawkins GA; Soker S; Thomas KW; Miller LD; Lu Y; Bellinger CR; Zhang W; Habib AA; Petty WJ; Zhao D
Nat Nanotechnol; 2022 Feb; 17(2):206-216. PubMed ID: 34916656
[TBL] [Abstract][Full Text] [Related]
9. EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway.
Tsai MF; Chang TH; Wu SG; Yang HY; Hsu YC; Yang PC; Shih JY
Sci Rep; 2015 Sep; 5():13574. PubMed ID: 26338423
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-alpha promotes malignant pleural effusion.
Stathopoulos GT; Kollintza A; Moschos C; Psallidas I; Sherrill TP; Pitsinos EN; Vassiliou S; Karatza M; Papiris SA; Graf D; Orphanidou D; Light RW; Roussos C; Blackwell TS; Kalomenidis I
Cancer Res; 2007 Oct; 67(20):9825-34. PubMed ID: 17942913
[TBL] [Abstract][Full Text] [Related]
11. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.
Stathopoulos GT; Psallidas I; Moustaki A; Moschos C; Kollintza A; Karabela S; Porfyridis I; Vassiliou S; Karatza M; Zhou Z; Joo M; Blackwell TS; Roussos C; Graf D; Kalomenidis I
J Natl Cancer Inst; 2008 Oct; 100(20):1464-76. PubMed ID: 18840818
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer.
Cui R; Takahashi F; Ohashi R; Yoshioka M; Gu T; Tajima K; Unnoura T; Iwakami S; Hirama M; Ishiwata T; Iwase A; Takahashi K
Lung Cancer; 2009 Mar; 63(3):368-74. PubMed ID: 18752867
[TBL] [Abstract][Full Text] [Related]
13. Icmt inhibition exerts anti-angiogenic and anti-hyperpermeability activities impeding malignant pleural effusion.
Magkouta S; Pappas A; Moschos C; Vazakidou ME; Psarra K; Kalomenidis I
Oncotarget; 2016 Apr; 7(15):20249-59. PubMed ID: 26959120
[TBL] [Abstract][Full Text] [Related]
14. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
[TBL] [Abstract][Full Text] [Related]
15. Analysis of B7-H4 expression in metastatic pleural adenocarcinoma and therapeutic potential of its antagonists.
Chen C; Qu QX; Xie F; Zhu WD; Zhu YH; Huang JA
BMC Cancer; 2017 Sep; 17(1):652. PubMed ID: 28923053
[TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin (mTOR) inhibition does not prevent lung adenocarcinoma-induced malignant pleural effusion.
Vazakidou ME; Magkouta S; Moschos C; Kalomenidis I
Respirology; 2014 Feb; 19(2):290-292. PubMed ID: 23819792
[TBL] [Abstract][Full Text] [Related]
17. Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation.
Zou J; Bella AE; Chen Z; Han X; Su C; Lei Y; Luo H
J Int Med Res; 2014 Oct; 42(5):1110-7. PubMed ID: 25239875
[TBL] [Abstract][Full Text] [Related]
18. Malignant pleural effusion from lung adenocarcinoma treated by gefitinib.
Kubo A; Koh Y; Kawaguchi T; Isa S; Okamoto I; Fukuoka J; Kusunoki Y; Kitaichi M; Takada M; Nakagawa K
Intern Med; 2011; 50(7):745-8. PubMed ID: 21467709
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion.
Marazioti A; Lilis I; Vreka M; Apostolopoulou H; Kalogeropoulou A; Giopanou I; Giotopoulou GA; Krontira AC; Iliopoulou M; Kanellakis NI; Agalioti T; Giannou AD; Jones-Paris C; Iwakura Y; Kardamakis D; Blackwell TS; Taraviras S; Spella M; Stathopoulos GT
Nat Commun; 2018 Feb; 9(1):672. PubMed ID: 29445180
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]